See more : Alterity Therapeutics Limited (ATHE) Income Statement Analysis – Financial Results
Complete financial analysis of Alembic Pharmaceuticals Limited (APLLTD.BO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Alembic Pharmaceuticals Limited, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Magnis Energy Technologies Limited (MNSEF) Income Statement Analysis – Financial Results
- NEXT Biometrics Group ASA (NEXT.OL) Income Statement Analysis – Financial Results
- Aceragen, Inc. (ACGN) Income Statement Analysis – Financial Results
- Northeast Pharmaceutical Group Co., Ltd. (000597.SZ) Income Statement Analysis – Financial Results
- Manufatura de Brinquedos Estrela S.A. (ESTR3.SA) Income Statement Analysis – Financial Results
Alembic Pharmaceuticals Limited (APLLTD.BO)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://alembicpharmaceuticals.com
About Alembic Pharmaceuticals Limited
Alembic Pharmaceuticals Limited develops, manufactures, and markets pharmaceutical products in India and internationally. The company provides branded specialty medicines in various therapeutic areas, such as cardiology, gynecology, gastrology, ophthalmology, dermatology, nephrology/urology, orthopedics, anti-infective, cold and cough, veterinary, and anti-diabetic; generics formulations in oral solids, oncology oral solids and injectables, general injectables and ophthalmic products, dermatology, and oral suspension; and active pharmaceutical ingredients. It also exports its products. Alembic Pharmaceuticals Limited was founded in 1907 and is headquartered in Vadodara, India.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 61.12B | 55.00B | 52.32B | 52.76B | 44.92B | 38.07B | 30.35B | 30.30B | 30.36B | 20.10B | 18.20B | 14.93B | 14.33B | 12.02B |
| Cost of Revenue | 39.60B | 20.23B | 17.23B | 15.21B | 13.14B | 11.93B | 10.62B | 10.19B | 9.38B | 7.58B | 7.59B | 7.16B | 7.48B | 5.90B |
| Gross Profit | 21.52B | 34.77B | 35.09B | 37.55B | 31.78B | 26.13B | 19.73B | 20.11B | 20.98B | 12.52B | 10.61B | 7.77B | 6.85B | 6.12B |
| Gross Profit Ratio | 35.21% | 63.21% | 67.06% | 71.17% | 70.75% | 68.65% | 65.00% | 66.38% | 69.11% | 62.28% | 58.29% | 52.05% | 47.82% | 50.88% |
| Research & Development | 4.39B | 290.70M | 505.90M | 253.80M | 426.40M | 302.70M | 368.60M | 982.00M | 911.20M | 1.22B | 1.16B | 743.04M | 585.82M | 471.32M |
| General & Administrative | 2.52B | 2.41B | 2.11B | 2.18B | 1.55B | 1.35B | 1.10B | 1.45B | 1.06B | 423.51M | 331.94M | 205.14M | 216.84M | 88.15M |
| Selling & Marketing | 9.97B | 9.52B | 8.90B | 6.87B | 5.31B | 5.90B | 3.80B | 3.93B | 2.74B | 2.45B | 1.94B | 1.55B | 1.30B | 923.41M |
| SG&A | 12.49B | 11.93B | 11.01B | 9.05B | 6.86B | 7.25B | 4.90B | 5.38B | 3.80B | 2.87B | 2.27B | 1.75B | 1.52B | 1.01B |
| Other Expenses | -181.50M | 2.70M | 1.30M | 2.00M | 200.00K | 2.30M | 300.00K | 1.60M | -73.80M | 17.32M | 10.04M | 0.00 | 4.37M | 0.00 |
| Operating Expenses | 15.87B | 30.23B | 29.16B | 24.58B | 20.67B | 18.59B | 14.63B | 14.71B | 11.62B | 8.99B | 7.40B | 5.63B | 4.93B | 4.80B |
| Cost & Expenses | 55.47B | 50.46B | 46.39B | 39.79B | 33.81B | 30.53B | 25.25B | 24.90B | 21.00B | 16.57B | 14.99B | 12.79B | 12.40B | 10.70B |
| Interest Income | 20.90M | 3.30M | 17.30M | 15.80M | 17.30M | 25.80M | 6.20M | 10.30M | 17.50M | 20.27M | 5.91M | 94.08M | 113.35M | 36.98M |
| Interest Expense | 561.90M | 501.70M | 177.30M | 160.20M | 271.60M | 184.10M | 34.00M | 52.30M | 54.30M | 38.08M | 104.00M | 239.82M | 375.48M | 275.87M |
| Depreciation & Amortization | 2.73B | 2.75B | 2.87B | 1.83B | 1.57B | 1.15B | 1.05B | 829.70M | 722.10M | 444.10M | 404.87M | 349.69M | 336.50M | 295.92M |
| EBITDA | 9.61B | 7.11B | 9.25B | 15.68B | 11.84B | 8.83B | 6.50B | 6.17B | 10.14B | 4.07B | 3.61B | 2.65B | 2.32B | 1.60B |
| EBITDA Ratio | 15.72% | 12.72% | 17.80% | 29.55% | 27.27% | 23.42% | 21.24% | 20.39% | 33.34% | 20.24% | 19.74% | 17.52% | 16.14% | 13.65% |
| Operating Income | 5.76B | 3.88B | 5.72B | 12.07B | 10.25B | 6.68B | 4.53B | 4.89B | 8.82B | 3.62B | 3.19B | 2.27B | 1.98B | 1.34B |
| Operating Income Ratio | 9.42% | 7.06% | 10.93% | 22.88% | 22.82% | 17.54% | 14.93% | 16.14% | 29.04% | 18.03% | 17.52% | 15.18% | 13.79% | 11.18% |
| Total Other Income/Expenses | 560.20M | -894.90M | 324.10M | 712.40M | -251.00M | -45.10M | 314.10M | -107.80M | -900.00K | 58.86M | -103.67M | -76.70M | -313.51M | -247.40M |
| Income Before Tax | 6.32B | 3.55B | 6.25B | 13.68B | 10.00B | 7.49B | 5.41B | 5.29B | 9.36B | 3.59B | 3.11B | 2.06B | 1.61B | 1.07B |
| Income Before Tax Ratio | 10.34% | 6.45% | 11.95% | 25.93% | 22.26% | 19.68% | 17.83% | 17.46% | 30.83% | 17.86% | 17.07% | 13.82% | 11.24% | 8.89% |
| Income Tax Expense | 160.00M | 126.10M | 1.04B | 2.53B | 1.99B | 1.57B | 1.20B | 1.22B | 2.16B | 763.49M | 751.03M | 411.00M | 308.50M | 214.56M |
| Net Income | 6.16B | 3.42B | 5.21B | 11.47B | 8.29B | 5.84B | 4.13B | 4.03B | 7.20B | 2.83B | 2.36B | 1.65B | 1.30B | 853.88M |
| Net Income Ratio | 10.08% | 6.22% | 9.96% | 21.73% | 18.45% | 15.35% | 13.60% | 13.31% | 23.72% | 14.08% | 12.94% | 11.07% | 9.08% | 7.10% |
| EPS | 31.33 | 17.40 | 26.50 | 59.18 | 43.97 | 31.00 | 21.89 | 21.39 | 38.19 | 15.01 | 12.49 | 8.77 | 6.90 | 4.53 |
| EPS Diluted | 31.33 | 17.40 | 26.50 | 59.18 | 43.97 | 31.00 | 21.89 | 21.39 | 38.19 | 15.01 | 12.49 | 8.77 | 6.90 | 4.53 |
| Weighted Avg Shares Out | 196.56M | 196.56M | 196.56M | 193.74M | 188.52M | 188.52M | 188.52M | 188.52M | 188.52M | 188.49M | 188.56M | 188.43M | 188.60M | 188.49M |
| Weighted Avg Shares Out (Dil) | 196.56M | 196.56M | 196.56M | 193.74M | 188.52M | 188.52M | 188.52M | 188.52M | 188.52M | 188.49M | 188.56M | 188.43M | 188.60M | 188.49M |
Source: https://incomestatements.info
Category: Stock Reports